|
|
| (3 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| |
| {{Carteolol}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
|
| |
|
| '''''For patient information about Carteolol, click [[Carteolol (patient information)|here]]'''''
| |
|
| |
| {{SB}} OCUPRESS<sup>®</sup>
| |
|
| |
| ==Overview==
| |
|
| |
| ==Category==
| |
|
| |
| ==FDA Package Insert==
| |
|
| |
| '''| [[Carteolol indications and usage|Indications and Usage]]'''
| |
| '''| [[Carteolol dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Carteolol dosage forms and strengths|Dosage Forms and Strengths]]'''
| |
| '''| [[Carteolol contraindications|Contraindications]]'''
| |
| '''| [[Carteolol warnings and precautions|Warnings and Precautions]]'''
| |
| '''| [[Carteolol adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Carteolol drug interactions|Drug Interactions]]'''
| |
| '''| [[Carteolol use in specific populations|Use in Specific Populations]]'''
| |
| '''| [[Carteolol overdosage|Overdosage]]'''
| |
| '''| [[Carteolol description|Description]]'''
| |
| '''| [[Carteolol clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Carteolol nonclinical toxicology|Nonclinical Toxicology]]'''
| |
| '''| [[Carteolol clinical studies|Clinical Studies]]'''
| |
| '''| [[Carteolol how supplied storage and handling|How Supplied/Storage and Handling]]'''
| |
| '''| [[Carteolol patient counseling information|Patient Counseling Information]]'''
| |
| '''| [[Carteolol labels and packages|Labels and Packages]]'''
| |
| ==Mechanism of Action==
| |
| Ocupress (carteolol HCl) reduces normal and elevated [[intraocular pressure]] ([[IOP]]) whether or not accompanied by [[glaucoma]]. The exact mechanism of the ocular hypotensive effect of beta-blockers has not been definitely demonstrated.
| |
| In general, beta-adrenergic blockers reduce [[cardiac output]] in patients in good and poor cardiovascular health. In patients with severe impairment of myocardial function, beta-blockers may inhibit the sympathetic stimulation necessary to maintain adequate cardiac function. Beta-adrenergic blockers may also increase airway resistance in the bronchi and bronchioles due to unopposed parasympathetic activity.
| |
|
| |
| ==References==
| |
|
| |
| {{Reflist|2}}
| |
|
| |
| [[Category:Beta blockers]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |